<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633971</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS 08-065</org_study_id>
    <nct_id>NCT00633971</nct_id>
  </id_info>
  <brief_title>Treatment Trial for Post-Thrombotic Syndrome</brief_title>
  <official_title>A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if complex lymphedema therapy is effective in&#xD;
      decreasing disease severity and improving quality of life in patients with post thrombotic&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post thrombotic syndrome (PTS) has a spectrum of disease manifestations ranging from minor&#xD;
      skin discoloration to severe skin changes and venous ulcerations. Pain is often a prominent&#xD;
      symptoms and PTS impairs patient quality of life. Prevention of PTS using compression&#xD;
      stockings has been emphasized. There is a paucity of validated, effective treatments for PTS&#xD;
      once the condition develops.&#xD;
&#xD;
      While the pathophysiology of PTS is incompletely understood, chronic venous hypertension and&#xD;
      insufficiency may increase the workload of the lymphatic system and result in&#xD;
      over-capacitance with secondary damage and eventual lymphatic insufficiency. In selected&#xD;
      patients with PTS, we have noted a symptomatic improvement in patients who receive lymphedema&#xD;
      therapy to the limb.&#xD;
&#xD;
      Complex lymphedema therapy (CLT) is a noninvasive treatment that includes four key&#xD;
      components: meticulous skin care, manual lymph drainage, compression therapy, exercises and&#xD;
      patient education for home management and continuation of the treatment. These techniques are&#xD;
      designed to enhance lymph flow through intact cutaneous lymphatics and reduce swelling and&#xD;
      restore function in the affected limb.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if complex lymphedema therapy improves the quality of life in patients with post-thrombotic syndrome</measure>
    <time_frame>1 and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine if complex lymphedema therapy reduces disease severity in patients with post thrombotic syndrome</measure>
    <time_frame>1 and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess side effects of lymphedema therapy when administered to patients with PTS</measure>
    <time_frame>1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if selected biomarkers correlate with disease severity and response to lymphedema therapy in patients with post thrombotic syndrome</measure>
    <time_frame>1 and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Post Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complex lymphedema therapy (which includes compression stocking use)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care (compression stocking use at 30-40 mm Hg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>complex lymphedema therapy</intervention_name>
    <description>Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  Diagnosis of post thrombotic syndrome.&#xD;
&#xD;
          -  Median life expectancy of greater than 2 years.&#xD;
&#xD;
          -  Previous history of lower extremity deep venous thrombosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute venous thrombosis of the lower extremity within the last 180 days.&#xD;
&#xD;
          -  Unable to participate in lymphedema therapy due to monetary, physical or&#xD;
             transportation limitations.&#xD;
&#xD;
          -  Uncontrolled illness including, but not limited to, ongoing or active infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          -  Pregnant women and women in their first post-partum month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris E Holmes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont and Fletcher Allen Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fletcher Allen Health Care; Department of Hematology/Oncology</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vermontcancer.org</url>
    <description>Dedicated to improving the human condition affected by cancer, through research in the laboratory and in the clinic, cancer prevention and control research and programs, state-of-the art cancer diagnosis.</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Chris Holmes</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Post thrombotic syndrome</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Venous thrombosis</keyword>
  <keyword>Edema</keyword>
  <keyword>stasis ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

